USE OF THIOSULFATE TO POTENTIATE THE ANTI-PATHOGENIC EFFECT OF LACTOBACILLI
The present disclosure relates to the use of thiosulfate to potentiate the anti-pathogenic effect of lactobacilli bacteria, the thiosulfate being in a quantity of at least 100 mg for 10 7 to 10 10 CFU of lactobacilli. The disclosure also relates to a pharmaceutical composition including at least 100 mg of thiosulfate per gram, in combination with a Lactobacillus crispatus strain, and to its use in the treatment of urogenital infections such as vaginosis, candidosis and urinary tract infections.
1 - 9 . (canceled)
10 . A method of using thiosulfate, the method comprising potentiating an anti-pathogenic effect of lactobacilli bacteria with the thiosulfate to treat urogenital infections such as vaginosis, candidiasis and urinary tract infections, the thiosulfate being in a quantity of at least 100 mg/gram of powder, for a powder including from 10 7 to 10 10 CFU/g of lactobacilli.
11 . The method according to claim 10 , wherein the thiosulfate is selected from sodium thiosulfate or potassium thiosulfate.
12 . The method according to claim 10 , further comprising using the thiosulfate in a quantity of about 230 mg/gram of powder, for a powder including between 10 7 and 10 10 CFU/g.
13 . The method according to claim 10 , wherein the lactobacilli are Lactobacillus rhamnosus and/or Lactobacillus crispatus.
14 . A pharmaceutical composition comprising at least 100 mg of thiosulfate per gram, in combination with a Lactobacillus crispatus strain.
15 . A pharmaceutical composition comprising a culture supernatant of a Lactobacillus strain cultivated in the presence of sodium thiosulfate, the supernatant not containing lactobacilli.
16 . The pharmaceutical composition according to claim 14 , formulated for vaginal or oral administration.
17 . The pharmaceutical composition according to claim 14 , adapted to treat urogenital infections such as vaginosis, candidosis and urinary tract infections.
18 . A pharmaceutical composition comprising at least 100 mg of thiosulfate per gram, in combination with 10 7 to 10 10 CFU/g of a Lactobacillus strain, adapted to treat urogenital infections such as vaginosis, candidosis and urinary tract infections, by potentiation of the anti-pathogenic effect of lactobacilli.